主页 > 医学信息 >
【技术产业】BMS出价$ 4.3亿美元收购 Adnexus 治疗公
Bristol-Myers agreed in February to pay about $30 million over three years to help tiny Adnexus develop its class of drugs, called Adnectins. They include an experimental cancer drug called Angiocept (CT-322), now in Phase 1 trials, and a range of other products in test-tube and animal studies.
AdvertisementAlthough Adnexus last month said it had filed with U.S. regulators for a public stock offering, it and Bristol-Myers jointly announced their merger deal Monday.
The net price is $415 million after deducting Adnexus' cash holdings. Bristol-Myers said it could pay up to $75 million more if Adnexus achieves certain development and regulatory milestones.
Waltham, Massachusetts-based Adnexus is owned by a handful of venture capital companies, including Venrock.
Anders Hove, a Venrock general partner, said Adnectins have properties similar to those of monoclonal antibodies, the popular class of biotech drugs now being used to treat an ever-increasing range of cancers and inflammatory diseases.
“But Adnectins are smaller and different from monoclonal antibodies, and thereby avoid (infringing) all patents of monoclonal antibodies,” he said.
Hove said Angiocept, in its trial, was shown to bind to and thereby theoretically block a major cancer target known as VEGF. That is the same tumor-nourishing protein blocked by Avastin, the blockbuster treatment for colon and lung cancer sold by Genentech Inc and Roche Holding AG.
John Mendlein, chief executive of Adnexus, said Avastin works by blocking only one variety of VEGF, whereas his drug blocks three forms of the protein.
“We have seen significant signs of stable disease, which is surprising in Phase 1 trials,” Mendlein said, noting that 25 patients with a variety of cancers are being studied in the Angiocept study.
New York-based Bristol-Myers, the world's biggest player in the oncology field until patents on its Taxol treatment lapsed several years ago, aims to develop new drugs to recover a leadership role in this highly profitable segment.
It said Adnexus' Adnectins have potential in treating cancer and other diseases and would bolster Bristol-Myers' expertise in “biologics,” the modern but hard-to-manufacture wave of medicines that are variations of naturally occurring human proteins.
Francis Cuss, a senior Bristol-Myers research executive, said his company became interested in buying Adnexus soon after their collaboration began early this year.
“Their people delivered higher-affinity binders than we expected,” he said, referring to potential drugs.
Large drugmakers like Bristol-Myers are having to pay higher and higher prices to acquire small biotechnology companies or license their experimental drugs.
Adnexus, for instance, has not even begun the mid-stage, or Phase II, human trials that traditionally provide “proof of concept” hints about the safety and effectiveness of medicines and their underlying technology.
Adnectins work by redirecting fibronectin, a human protein that is naturally abundant in the bloodstream, in ways that treat various diseases, according to Bristol-Myers and Adnexus.
The companies said the experimental drugs are manufactured using a patented process that can simultaneously create trillions of protein combinations and screen them for optimal drug qualities – including potency, stability and specificity for given drug targets.
Bristol-Myers shares edged down 21 cents to $28.79 in late-afternoon New York Stock Exchange trade, amid a slight decline for the drug sector 本人认领编译本文，48小时内若未提供编译文稿，请其他战友自由认领 NEW YORK – Bristol-Myers Squibb Co said Monday it would pay $430 million for Adnexus Therapeutics, a privately held biotechnology company whose lead product is a cancer drug in the earliest stages of human trials.
纽约——百时美施贵宝公司（BMS公司）称他们在星期一将支付430亿美元收购Adnexus医疗公司，Adnexus公司是一家私人所有的生物技术公司，其主要产品用于早期阶段人体试验的治癌症的药物。
Bristol-Myers agreed in February to pay about $30 million over three years to help tiny Adnexus develop its class of drugs, called Adnectins. They include an experimental cancer drug called Angiocept (CT-322), now in Phase 1 trials, and a range of other products in test-tube and animal studies. [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-07-05 05:52
医学,生命科学网